請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/36974
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陶秘華 | |
dc.contributor.author | Ho-Yuan Chou | en |
dc.contributor.author | 周和源 | zh_TW |
dc.date.accessioned | 2021-06-13T15:17:25Z | - |
dc.date.available | 2013-10-07 | |
dc.date.copyright | 2011-10-07 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-08-11 | |
dc.identifier.citation | 1. Summers, J., and W. S. Mason. 1982. Replication of the genome of a hepatitis B--like virus by reverse transcription of an RNA intermediate. Cell 29: 403-415.
2. Liaw, Y. F., and C. M. Chu. 2009. Hepatitis B virus infection. Lancet 373: 582-592. 3. Kao, J. H. 2007. Role of viral factors in the natural course and therapy of chronic hepatitis B. Hepatol. Int. 1: 415-430. 4. Chen, C. C., C. M. Chang, C. P. Sun, C. P. Yu, P. Y. Wu, K. S. Jeng, C. P. Hu, P. J. Chen, J. C. Wu, C. H. Shih, M. E. Gershwin, and M. H. Tao. 2011. Use of RNA interference to modulate liver adenoma development in a murine model transgenic for hepatitis B virus. Gene Ther. Online publication 12 May 2011. 5. Lavanchy, D. 2004. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepat. 11: 97-107. 6. Huang, Y. H., C. C. Fang, K. Tsuneyama, H. Y. Chou, W. Y. Pan, Y. M. Shih, P. Y. Wu, Y. Chen, P. S. Leung, M. E. Gershwin, and M. H. Tao. 2011. A murine model of hepatitis B-associated hepatocellular carcinoma generated by adeno-associated virus-mediated gene delivery. Int. J. Oncol. Online publication 28 July 2011. 7. Crettaz, J., I. Otano, L. Ochoa, A. Benito, A. Paneda, I. Aurrekoetxea, P. Berraondo, J. R. Rodriguez-Madoz, A. Astudillo, F. Kreppel, S. Kochanek, J. Ruiz, S. Menne, J. Prieto, and G. Gonzalez-Aseguinolaza. 2009. Treatment of chronic viral hepatitis in woodchucks by prolonged intrahepatic expression of interleukin-12. J. Virol. 83: 2663-2674. 8. Chen, C. C., T. M. Ko, H. I. Ma, H. L. Wu, X. Xiao, J. Li, C. M. Chang, P. Y. Wu, C. H. Chen, J. M. Han, C. P. Yu, K. S. Jeng, C. P. Hu, and M. H. Tao. 2007. Long-term inhibition of hepatitis B virus in transgenic mice by double-stranded adeno-associated virus 8-delivered short hairpin RNA. Gene Ther. 14: 11-19. 9. Kurose, K., S. M. Akbar, K. Yamamoto, and M. Onji. 1997. Production of antibody to hepatitis B surface antigen (anti-HBs) by murine hepatitis B virus carriers: neonatal tolerance versus antigen presentation by dendritic cells. Immunology 92: 494-500. 10. Murray, J. M., S. F. Wieland, R. H. Purcell, and F. V. Chisari. 2005. Dynamics of hepatitis B virus clearance in chimpanzees. Proc. Natl. Acad. Sci. USA 102: 17780-17785. 11. Guidotti, L. G., R. Rochford, J. Chung, M. Shapiro, R. Purcell, and F. V. Chisari. 1999. Viral clearance without destruction of infected cells during acute HBV infection. Science 284: 825-829. 12. Boonstra, A., A. M. Woltman, and H. L. Janssen. 2008. Immunology of hepatitis B and hepatitis C virus infections. Best Pract. Res. Clin. Gastroenterol. 22: 1049-1061. 13. Thimme, R., S. Wieland, C. Steiger, J. Ghrayeb, K. A. Reimann, R. H. Purcell, and F. V. Chisari. 2003. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J. Virol. 77: 68-76. 14. Maini, M. K., C. Boni, C. K. Lee, J. R. Larrubia, S. Reignat, G. S. Ogg, A. S. King, J. Herberg, R. Gilson, A. Alisa, R. Williams, D. Vergani, N. V. Naoumov, C. Ferrari, and A. Bertoletti. 2000. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J. Exp. Med. 191: 1269-1280. 15. McMahon, B. J., W. L. Alward, D. B. Hall, W. L. Heyward, T. R. Bender, D. P. Francis, and J. E. Maynard. 1985. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J. Infect. Dis. 151: 599-603. 16. Chen, H. L., C. J. Chang, M. S. Kong, F. C. Huang, H. C. Lee, C. C. Lin, C. C. Liu, I. H. Lee, T. C. Wu, S. F. Wu, Y. H. Ni, H. Y. Hsu, D. S. Chen, and M. H. Chang. 2004. Pediatric fulminant hepatic failure in endemic areas of hepatitis B infection: 15 years after universal hepatitis B vaccination. Hepatology 39: 58-63. 17. Tsui, L. V., L. G. Guidotti, T. Ishikawa, and F. V. Chisari. 1995. Posttranscriptional clearance of hepatitis B virus RNA by cytotoxic T lymphocyte-activated hepatocytes. Proc. Natl. Acad. Sci. USA 92: 12398-12402. 18. Penna, A., F. V. Chisari, A. Bertoletti, G. Missale, P. Fowler, T. Giuberti, F. Fiaccadori, and C. Ferrari. 1991. Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J. Exp. Med. 174: 1565-1570. 19. Rehermann, B., P. Fowler, J. Sidney, J. Person, A. Redeker, M. Brown, B. Moss, A. Sette, and F. V. Chisari. 1995. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J. Exp. Med. 181: 1047-1058. 20. Bertoletti, A., C. Ferrari, F. Fiaccadori, A. Penna, R. Margolskee, H. J. Schlicht, P. Fowler, S. Guilhot, and F. V. Chisari. 1991. HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc. Natl. Acad. Sci. USA 88: 10445-10449. 21. Molina, V., and Y. Shoenfeld. 2005. Infection, vaccines and other environmental triggers of autoimmunity. Autoimmunity 38: 235-245. 22. Ferrari, C., A. Penna, A. Bertoletti, A. Valli, A. D. Antoni, T. Giuberti, A. Cavalli, M. A. Petit, and F. Fiaccadori. 1990. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J. Immunol. 145: 3442-3449. 23. Jung, M. C., U. Spengler, W. Schraut, R. Hoffmann, R. Zachoval, J. Eisenburg, D. Eichenlaub, G. Riethmuller, G. Paumgartner, H. W. Ziegler-Heitbrock, and et al. 1991. Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B. J. Hepatol. 13: 310-317. 24. Chen, D. S. 2009. Hepatitis B vaccination: The key towards elimination and eradication of hepatitis B. J. Hepatol. 50: 805-816. 25. Chen, H. L., M. H. Chang, Y. H. Ni, H. Y. Hsu, P. I. Lee, C. Y. Lee, and D. S. Chen. 1996. Seroepidemiology of hepatitis B virus infection in children: Ten years of mass vaccination in Taiwan. JAMA 276: 906-908. 26. Viviani, S., A. Jack, A. J. Hall, N. Maine, M. Mendy, R. Montesano, and H. C. Whittle. 1999. Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age. Vaccine 17: 2946-2950. 27. Chang, M. H., C. J. Chen, M. S. Lai, H. M. Hsu, T. C. Wu, M. S. Kong, D. C. Liang, W. Y. Shau, and D. S. Chen. 1997. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N. Engl. J. Med. 336: 1855-1859. 28. Dienstag, J. L., B. G. Werner, B. F. Polk, D. R. Snydman, D. E. Craven, R. Platt, C. S. Crumpacker, R. Ouellet-Hellstrom, and G. F. Grady. 1984. Hepatitis B vaccine in health care personnel: safety, immunogenicity, and indicators of efficacy. Ann. Intern. Med. 101: 34-40. 29. Crosnier, J., P. Jungers, A. M. Courouce, A. Laplanche, E. Benhamou, F. Degos, B. Lacour, P. Prunet, Y. Cerisier, and P. Guesry. 1981. Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in french haemodialysis units: II, Haemodialysis patients. Lancet 1: 797-800. 30. Stevens, C. E., H. J. Alter, P. E. Taylor, E. A. Zang, E. J. Harley, and W. Szmuness. 1984. Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N. Engl. J. Med. 311: 496-501. 31. Milich, D. R., and G. G. Leroux-Roels. 2003. Immunogenetics of the response to HBsAg vaccination. Autoimmun Rev. 2: 248-257. 32. Egea, E., A. Iglesias, M. Salazar, C. Morimoto, M. S. Kruskall, Z. Awdeh, S. F. Schlossman, C. A. Alper, and E. J. Yunis. 1991. The cellular basis for lack of antibody response to hepatitis B vaccine in humans. J. Exp. Med. 173: 531-538. 33. Missale, G., R. Bertoni, V. Lamonaca, A. Valli, M. Massari, C. Mori, M. G. Rumi, M. Houghton, F. Fiaccadori, and C. Ferrari. 1996. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J. Clin. Invest. 98: 706-714. 34. Lechner, F., D. K. Wong, P. R. Dunbar, R. Chapman, R. T. Chung, P. Dohrenwend, G. Robbins, R. Phillips, P. Klenerman, and B. D. Walker. 2000. Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med. 191: 1499-1512. 35. Boni, C., P. Fisicaro, C. Valdatta, B. Amadei, P. Di Vincenzo, T. Giuberti, D. Laccabue, A. Zerbini, A. Cavalli, G. Missale, A. Bertoletti, and C. Ferrari. 2007. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J. Virol. 81: 4215-4225. 36. Manigold, T., and V. Racanelli. 2007. T-cell regulation by CD4 regulatory T cells during hepatitis B and C virus infections: facts and controversies. Lancet Infect Di.s 7: 804-813. 37. Wherry, E. J., J. N. Blattman, K. Murali-Krishna, R. van der Most, and R. Ahmed. 2003. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 77: 4911-4927. 38. Zhou, S., R. Ou, L. Huang, G. E. Price, and D. Moskophidis. 2004. Differential tissue-specific regulation of antiviral CD8+ T-cell immune responses during chronic viral infection. J. Virol. 78: 3578-3600. 39. Mikaeloff, Y., G. Caridade, S. Suissa, and M. Tardieu. 2009. Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood. Neurology 72: 873-880. 40. Wherry, E. J., and R. Ahmed. 2004. Memory CD8 T-cell differentiation during viral infection. J. Virol. 78: 5535-5545. 41. Asabe, S., S. F. Wieland, P. K. Chattopadhyay, M. Roederer, R. E. Engle, R. H. Purcell, and F. V. Chisari. 2009. The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J. Virol. 83: 9652-9662. 42. Sobao, Y., H. Tomiyama, K. Sugi, M. Tokunaga, T. Ueno, S. Saito, S. Fujiyama, M. Morimoto, K. Tanaka, and M. Takiguchi. 2002. The role of hepatitis B virus-specific memory CD8 T cells in the control of viral replication. J. Hepatol. 36: 105-115. 43. Webster, G. J., S. Reignat, D. Brown, G. S. Ogg, L. Jones, S. L. Seneviratne, R. Williams, G. Dusheiko, and A. Bertoletti. 2004. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J. Virol. 78: 5707-5719. 44. Ascherio, A., S. M. Zhang, M. A. Hernan, M. J. Olek, P. M. Coplan, K. Brodovicz, and A. M. Walker. 2001. Hepatitis B vaccination and the risk of multiple sclerosis. N. Engl. J. Med. 344: 327-332. 45. Belkaid, Y., and B. T. Rouse. 2005. Natural regulatory T cells in infectious disease. Nat. Immunol. 6: 353-360. 46. Fernandez, M. A., F. K. Puttur, Y. M. Wang, W. Howden, S. I. Alexander, and C. A. Jones. 2008. T regulatory cells contribute to the attenuated primary CD8+ and CD4+ T cell responses to herpes simplex virus type 2 in neonatal mice. J. Immunol. 180: 1556-1564. 47. Suvas, S., U. Kumaraguru, C. D. Pack, S. Lee, and B. T. Rouse. 2003. CD4+CD25+ T cells regulate virus-specific primary and memory CD8+ T cell responses. J. Exp. Med. 198: 889-901. 48. Lund, J. M., L. Hsing, T. T. Pham, and A. Y. Rudensky. 2008. Coordination of early protective immunity to viral infection by regulatory T cells. Science 320: 1220-1224. 49. Sharpe, A. H., E. J. Wherry, R. Ahmed, and G. J. Freeman. 2007. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunol. 8: 239-245. 50. Li, S., E. J. Gowans, C. Chougnet, M. Plebanski, and U. Dittmer. 2008. Natural regulatory T cells and persistent viral infection. J. Virol. 82: 21-30. 51. Yang, G., A. Liu, Q. Xie, T. B. Guo, B. Wan, B. Zhou, and J. Z. Zhang. 2007. Association of CD4+CD25+Foxp3+ regulatory T cells with chronic activity and viral clearance in patients with hepatitis B. Int. Immunol. 19: 133-140. 52. Franzese, O., P. T. Kennedy, A. J. Gehring, J. Gotto, R. Williams, M. K. Maini, and A. Bertoletti. 2005. Modulation of the CD8+-T-cell response by CD4+ CD25+ regulatory T cells in patients with hepatitis B virus infection. J. Virol. 79: 3322-3328. 53. Das, S., G. Suarez, E. J. Beswick, J. C. Sierra, D. Y. Graham, and V. E. Reyes. 2006. Expression of B7-H1 on gastric epithelial cells: its potential role in regulating T cells during Helicobacter pylori infection. J. Immunol. 176: 3000-3009. 54. Stoop, J. N., R. G. van der Molen, C. C. Baan, L. J. van der Laan, E. J. Kuipers, J. G. Kusters, and H. L. Janssen. 2005. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 41: 771-778. 55. Xu, D., J. Fu, L. Jin, H. Zhang, C. Zhou, Z. Zou, J. M. Zhao, B. Zhang, M. Shi, X. Ding, Z. Tang, Y. X. Fu, and F. S. Wang. 2006. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J. Immunol. 177: 739-747. 56. Nurieva, R. I., X. Liu, and C. Dong. 2009. Yin-Yang of costimulation: crucial controls of immune tolerance and function. Immunol. Rev. 229: 88-100. 57. Beswick, E. J., I. V. Pinchuk, S. Das, D. W. Powell, and V. E. Reyes. 2007. Expression of the programmed death ligand 1, B7-H1, on gastric epithelial cells after Helicobacter pylori exposure promotes development of CD4+ CD25+ FoxP3+ regulatory T cells. Infect. Immun. 75: 4334-4341. 58. Geng, L., G. Jiang, Y. Fang, S. Dong, H. Xie, Y. Chen, M. Shen, and S. Zheng. 2006. B7-H1 expression is upregulated in peripheral blood CD14+ monocytes of patients with chronic hepatitis B virus infection, which correlates with higher serum IL-10 levels. J. Viral Hepatitis 13: 725-733. 59. Yu, M. W., H. C. Chang, Y. F. Liaw, S. M. Lin, S. D. Lee, C. J. Liu, P. J. Chen, T. J. Hsiao, P. H. Lee, and C. J. Chen. 2000. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J. Natl. Cancer Inst. 92: 1159-1164. 60. Chen, C. J., H. I. Yang, J. Su, C. L. Jen, S. L. You, S. N. Lu, G. T. Huang, and U. H. Iloeje. 2006. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295: 65-73. 61. Kao, J. H., P. J. Chen, M. Y. Lai, and D. S. Chen. 2003. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 124: 327-334. 62. Chan, H. L., A. Y. Hui, M. L. Wong, A. M. Tse, L. C. Hung, V. W. Wong, and J. J. Sung. 2004. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 53: 1494-1498. 63. Yu, M. W., S. H. Yeh, P. J. Chen, Y. F. Liaw, C. L. Lin, C. J. Liu, W. L. Shih, J. H. Kao, D. S. Chen, and C. J. Chen. 2005. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J. Natl. Cancer Inst. 97: 265-272. 64. Chen, C. H., C. H. Hung, C. M. Lee, T. H. Hu, J. H. Wang, J. C. Wang, S. N. Lu, and C. S. Changchien. 2007. Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. Gastroenterology 133: 1466-1474. 65. Chou, Y. C., M. W. Yu, C. F. Wu, S. Y. Yang, C. L. Lin, C. J. Liu, W. L. Shih, P. J. Chen, Y. F. Liaw, and C. J. Chen. 2008. Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma. Gut 57: 91-97. 66. Chen, C. J., H. I. Yang, J. Su, C. L. Jen, S. L. You, S. N. Lu, G. T. Huang, and U. H. Iloeje. 2006. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295: 65-73. 67. Chisari, F. V. 2000. Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B. Am J Pathol 156: 1117-1132. 68. Guidotti, L. G., and F. V. Chisari. 2006. Immunobiology and pathogenesis of viral hepatitis. Annu. Rev. Pathol. 1: 23-61. 69. Guidotti, L. G., B. Matzke, H. Schaller, and F. V. Chisari. 1995. High-level hepatitis B virus replication in transgenic mice. J. Virol. 69: 6158-6169. 70. Chisari, F. V., M. Isogawa, and S. F. Wieland. 2010. Pathogenesis of hepatitis B virus infection. Pathol. Biol. (Paris) 58: 258-266. 71. Matsubara, K., and T. Tokino. 1990. Integration of hepatitis B virus DNA and its implications for hepatocarcinogenesis. Mol. Biol. Med. 7: 243-260. 72. Bruni, R., E. D'Ugo, R. Giuseppetti, C. Argentini, and M. Rapicetta. 1999. Activation of the N-myc2 oncogene by woodchuck hepatitis virus integration in the linked downstream b3n locus in woodchuck hepatocellular carcinoma. Virology 257: 483-490. 73. Bruni, R., E. D'Ugo, U. Villano, G. Fourel, M. A. Buendia, and M. Rapicetta. 2004. The win locus involved in activation of the distal N-myc2 gene upon WHV integration in woodchuck liver tumors harbors S/MAR elements. Virology 329: 1-10. 74. Paterlini-Brechot, P., K. Saigo, Y. Murakami, M. Chami, D. Gozuacik, C. Mugnier, D. Lagorce, and C. Brechot. 2003. Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. Oncogene 22: 3911-3916. 75. Murakami, Y., K. Saigo, H. Takashima, M. Minami, T. Okanoue, C. Brechot, and P. Paterlini-Brechot. 2005. Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas. Gut 54: 1162-1168. 76. Tamori, A., Y. Yamanishi, S. Kawashima, M. Kanehisa, M. Enomoto, H. Tanaka, S. Kubo, S. Shiomi, and S. Nishiguchi. 2005. Alteration of gene expression in human hepatocellular carcinoma with integrated hepatitis B virus DNA. Clin. Cancer Res.11: 5821-5826. 77. Ferber, M. J., D. P. Montoya, C. Yu, I. Aderca, A. McGee, E. C. Thorland, D. M. Nagorney, B. S. Gostout, L. J. Burgart, L. Boix, J. Bruix, B. J. McMahon, T. H. Cheung, T. K. Chung, Y. F. Wong, D. I. Smith, and L. R. Roberts. 2003. Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers. Oncogene 22: 3813-3820. 78. Minami, M., Y. Daimon, K. Mori, H. Takashima, T. Nakajima, Y. Itoh, and T. Okanoue. 2005. Hepatitis B virus-related insertional mutagenesis in chronic hepatitis B patients as an early drastic genetic change leading to hepatocarcinogenesis. Oncogene 24: 4340-4348. 79. Kekule, A. S., U. Lauer, L. Weiss, B. Luber, and P. H. Hofschneider. 1993. Hepatitis B virus transactivator HBx uses a tumour promoter signalling pathway. Nature 361: 742-745. 80. Maguire, H. F., J. P. Hoeffler, and A. Siddiqui. 1991. HBV X protein alters the DNA binding specificity of CREB and ATF-2 by protein-protein interactions. Science 252: 842-844. 81. Kremsdorf, D., P. Soussan, P. Paterlini-Brechot, and C. Brechot. 2006. Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis. Oncogene 25: 3823-3833. 82. Brechot, C. 2004. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology 127: S56-61. 83. Iavarone, M., J. B. Trabut, O. Delpuech, F. Carnot, M. Colombo, D. Kremsdorf, C. Brechot, and V. Thiers. 2003. Characterisation of hepatitis B virus X protein mutants in tumour and non-tumour liver cells using laser capture microdissection. J. Hepatol. 39: 253-261. 84. Kuang, S. Y., P. E. Jackson, J. B. Wang, P. X. Lu, A. Munoz, G. S. Qian, T. W. Kensler, and J. D. Groopman. 2004. Specific mutations of hepatitis B virus in plasma predict liver cancer development. Proc. Natl. Acad. Sci. USA 101: 3575-3580. 85. Koike, K., K. Moriya, S. Iino, H. Yotsuyanagi, Y. Endo, T. Miyamura, and K. Kurokawa. 1994. High-level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice. Hepatology 19: 810-819. 86. Caselmann, W. H., M. Meyer, A. S. Kekule, U. Lauer, P. H. Hofschneider, and R. Koshy. 1990. A trans-activator function is generated by integration of hepatitis B virus preS/S sequences in human hepatocellular carcinoma DNA. Proc. Natl. Acad. Sci. USA 87: 2970-2974. 87. Kekule, A. S., U. Lauer, M. Meyer, W. H. Caselmann, P. H. Hofschneider, and R. Koshy. 1990. The preS2/S region of integrated hepatitis B virus DNA encodes a transcriptional transactivator. Nature 343: 457-461. 88. Hildt, E., G. Saher, V. Bruss, and P. H. Hofschneider. 1996. The hepatitis B virus large surface protein (LHBs) is a transcriptional activator. Virology 225: 235-239. 89. Caselmann, W. H., M. Renner, V. Schluter, P. H. Hofschneider, R. Koshy, and M. Meyer. 1997. The hepatitis B virus MHBst167 protein is a pleiotropic transactivator mediating its effect via ubiquitous cellular transcription factors. J. Gen. Virol. 78 ( Pt 6): 1487-1495. 90. Natoli, G., M. L. Avantaggiati, C. Balsano, E. De Marzio, D. Collepardo, E. Elfassi, and M. Levrero. 1992. Characterization of the hepatitis B virus preS/S region encoded transcriptional transactivator. Virology 187: 663-670. 91. Lieber, C. S., A. Garro, M. A. Leo, K. M. Mak, and T. Worner. 1986. Alcohol and cancer. Hepatology 6: 1005-1019. 92. Niederau, C., R. Fischer, A. Sonnenberg, W. Stremmel, H. J. Trampisch, and G. Strohmeyer. 1985. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N. Engl. J. Med. 313: 1256-1262. 93. Limmer, J., W. E. Fleig, D. Leupold, R. Bittner, H. Ditschuneit, and H. G. Beger. 1988. Hepatocellular carcinoma in type I glycogen storage disease. Hepatology 8: 531-537. 94. Eriksson, S., J. Carlson, and R. Velez. 1986. Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency. N. Engl. J. Med. 314: 736-739. 95. Melia, W. M., P. J. Johnson, J. Neuberger, S. Zaman, B. C. Portmann, and R. Williams. 1984. Hepatocellular carcinoma in primary biliary cirrhosis: detection by alpha-fetoprotein estimation. Gastroenterology 87: 660-663. 96. Perrillo, R. 2009. Benefits and risks of interferon therapy for hepatitis B. Hepatology 49: S103-111. 97. Dienstag, J. L. 2009. Benefits and risks of nucleoside analog therapy for hepatitis B. Hepatology 49: S112-121. 98. Livingston, B. D., C. Crimi, H. Grey, G. Ishioka, F. V. Chisari, J. Fikes, R. W. Chesnut, and A. Sette. 1997. The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection. J. Immunol. 159: 1383-1392. 99. Vitiello, A., G. Ishioka, H. M. Grey, R. Rose, P. Farness, R. LaFond, L. Yuan, F. V. Chisari, J. Furze, R. Bartholomeuz, and et al. 1995. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J. Clin. Invest. 95: 341-349. 100. Mancini, M., M. Hadchouel, H. L. Davis, R. G. Whalen, P. Tiollais, and M. L. Michel. 1996. DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state. Proc. Natl. Acad. Sci. USA 93: 12496-12501. 101. Shimizu, Y., L. G. Guidotti, P. Fowler, and F. V. Chisari. 1998. Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice. J. Immunol. 161: 4520-4529. 102. Hsieh, J. H., K. Y. Shih, H. F. Kung, M. Shiang, L. Y. Lee, M. H. Meng, C. C. Chang, H. M. Lin, S. C. Shih, S. Y. Lee, T. Y. Chow, T. Y. Feng, T. T. Kuo, and K. B. Choo. 1988. Controlled fed-batch fermentation of recombinant Saccharomyces cerevisiae to produce hepatitis B surface antigen. Biotechnol Bioeng 32: 334-340. 103. Chow, Y. H., B. L. Chiang, Y. L. Lee, W. K. Chi, W. C. Lin, Y. T. Chen, and M. H. Tao. 1998. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes. J. Immunol. 160: 1320-1329. 104. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392: 245-252. 105. Morrissey, P. J., L. Bressler, L. S. Park, A. Alpert, and S. Gillis. 1987. Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells. J. Immunol. 139: 1113-1119. 106. Craven, D. E., Z. L. Awdeh, L. M. Kunches, E. J. Yunis, J. L. Dienstag, B. G. Werner, B. F. Polk, D. R. Syndman, R. Platt, C. S. Crumpacker, and et al. 1986. Nonresponsiveness to hepatitis B vaccine in health care workers. Results of revaccination and genetic typings. Ann. Intern. Med. 105: 356-360. 107. Alper, C. A., M. S. Kruskall, D. Marcus-Bagley, D. E. Craven, A. J. Katz, S. J. Brink, J. L. Dienstag, Z. Awdeh, and E. J. Yunis. 1989. Genetic prediction of nonresponse to hepatitis B vaccine. N. Engl. J. Med. 321: 708-712. 108. Milich, D. R., and F. V. Chisari. 1982. Genetic regulation of the immune response to hepatitis B surface antigen (HBsAg). I. H-2 restriction of the murine humoral immune response to the a and d determinants of HBsAg. J. Immunol. 129: 320-325. 109. Chiou, S. S., K. Yamauchi, T. Nakanishi, and H. Obata. 1988. Nature of immunological non-responsiveness to hepatitis B vaccine in healthy individuals. Immunology 64: 545-550. 110. Shokrgozar, M. A., and F. Shokri. 2001. Enumeration of hepatitis B surface antigen-specific B lymphocytes in responder and non-responder normal individuals vaccinated with recombinant hepatitis B surface antigen. Immunology 104: 75-79. 111. Vingerhoets, J., G. Vanham, L. Kestens, G. Penne, G. Leroux-Roels, and P. Gigase. 1994. Deficient T-cell responses in non-responders to hepatitis B vaccination: absence of TH1 cytokine production. Immunol. Lett. 39: 163-168. 112. Chedid, M. G., H. Deulofeut, D. E. Yunis, M. L. Lara-Marquez, M. Salazar, R. Deulofeut, Z. Awdeh, C. A. Alper, and E. J. Yunis. 1997. Defect in Th1-like cells of nonresponders to hepatitis B vaccine. Hum. Immunol. 58: 42-51. 113. Larsen, C. E., J. Xu, S. Lee, D. P. Dubey, G. Uko, E. J. Yunis, and C. A. Alper. 2000. Complex cytokine responses to hepatitis B surface antigen and tetanus toxoid in responders, nonresponders and subjects naive to hepatitis B surface antigen. Vaccine 18: 3021-3030. 114. Goncalves, L., B. Albarran, S. Salmen, L. Borges, H. Fields, H. Montes, A. Soyano, Y. Diaz, and L. Berrueta. 2004. The nonresponse to hepatitis B vaccination is associated with impaired lymphocyte activation. Virology 326: 20-28. 115. Goldwater, P. N. 1997. Randomized, comparative trial of 20 micrograms vs 40 micrograms Engerix B vaccine in hepatitis B vaccine non-responders. Vaccine 15: 353-356. 116. Fazle Akbar, S. M., S. Furukawa, O. Yoshida, Y. Hiasa, N. Horiike, and M. Onji. 2007. Induction of anti-HBs in HB vaccine nonresponders in vivo by hepatitis B surface antigen-pulsed blood dendritic cells. J. Hepatol. 47: 60-66. 117. Milich, D. R., M. K. McNamara, A. McLachlan, G. B. Thornton, and F. V. Chisari. 1985. Distinct H-2-linked regulation of T-cell responses to the pre-S and S regions of the same hepatitis B surface antigen polypeptide allows circumvention of nonresponsiveness to the S region. Proc. Natl. Acad. Sci. USA 82: 8168-8172. 118. Milich, D. R., G. B. Thornton, A. R. Neurath, S. B. Kent, M. L. Michel, P. Tiollais, and F. V. Chisari. 1985. Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen. Science 228: 1195-1199. 119. Bertino, J. S., Jr., P. Tirrell, R. N. Greenberg, H. L. Keyserling, G. A. Poland, D. Gump, M. L. Kumar, and K. Ramsey. 1997. A comparative trial of standard or high-dose S subunit recombinant hepatitis B vaccine versus a vaccine containing S subunit, pre-S1, and pre-S2 particles for revaccination of healthy adult nonresponders. J. Infect. Dis. 175: 678-681. 120. Leroux-Roels, G., I. Desombere, L. Cobbaut, M. A. Petit, P. Desmons, P. Hauser, A. Delem, D. De Grave, and A. Safary. 1997. Hepatitis B vaccine containing surface antigen and selected preS1 and preS2 sequences. 2. Immunogenicity in poor responders to hepatitis B vaccines. Vaccine 15: 1732-1736. 121. Zuckerman, J. N., A. J. Zuckerman, I. Symington, W. Du, A. Williams, B. Dickson, and M. D. Young. 2001. Evaluation of a new hepatitis B triple-antigen vaccine in inadequate responders to current vaccines. Hepatology 34: 798-802. 122. Milich, D. R., J. L. Hughes, A. McLachlan, K. E. Langley, G. B. Thornton, and J. E. Jones. 1990. Importance of subtype in the immune response to the pre-S(2) region of the hepatitis B surface antigen. I. T cell fine specificity. J. Immunol. 144: 3535-3543. 123. Pai, S. S., R. D. Tilton, and T. M. Przybycien. 2009. Poly(ethylene glycol)-modified proteins: implications for poly(lactide-co-glycolide)-based microsphere delivery. AAPS J. 11: 88-98. 124. Warren, T. L., and G. J. Weiner. 2000. Uses of granulocyte-macrophage colony-stimulating factor in vaccine development. Curr. Opin. Hematol. 7: 168-173. 125. Chang, D. Z., W. Lomazow, C. Joy Somberg, R. Stan, and M. A. Perales. 2004. Granulocyte-macrophage colony stimulating factor: an adjuvant for cancer vaccines. Hematology 9: 207-215. 126. Kim, M. J., A. N. Nafziger, C. D. Harro, H. L. Keyserling, K. M. Ramsey, G. L. Drusano, and J. S. Bertino, Jr. 2003. Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response. Vaccine 21: 1174-1179. 127. Kapoor, D., S. R. Aggarwal, N. P. Singh, V. Thakur, and S. K. Sarin. 1999. Granulocyte-macrophage colony-stimulating factor enhances the efficacy of hepatitis B virus vaccine in previously unvaccinated haemodialysis patients. J. Viral. Hepat. 6: 405-409. 128. Murray, J. M., S. F. Wieland, R. H. Purcell, and F. V. Chisari. 2005. Dynamics of hepatitis B virus clearance in chimpanzees. Proc. Natl. Acad. Sci. USA 102: 17780-17785. 129. Anandh, U., B. Bastani, and S. Ballal. 2000. Granulocyte-macrophage colony-stimulating factor as an adjuvant to hepatitis B vaccination in maintenance hemodialysis patients. Am. J. Nephrol. 20: 53-56. 130. Evans, T. G., M. Schiff, B. Graves, J. Agosti, M. L. Barritt, D. Garner, and J. L. Holley. 2000. The safety and efficacy of GM-CSF as an adjuvant in hepatitis B vaccination of chronic hemodialysis patients who have failed primary vaccination. Clin. Nephrol. 54: 138-142. 131. Jha, R., S. Lakhtakia, M. A. Jaleel, G. Narayan, and K. Hemlatha. 2001. Granulocyte macrophage colony stimulating factor (GM-CSF) induced sero-protection in end stage renal failure patients to hepatitis B in vaccine non-responders. Ren. Fail. 23: 629-636. 132. Singh, N. P., S. K. Mandal, A. Thakur, D. Kapoor, S. Anuradha, A. Prakash, R. Kohli, and S. K. Agarwal. 2003. Efficacy of GM-CSF as an adjuvant to hepatitis B vaccination in patients with chronic renal failure--results of a prospective, randomized trial. Ren. Fail. 25: 255-266. 133. Cruciani, M., C. Mengoli, G. Serpelloni, R. Mazzi, O. Bosco, and M. Malena. 2007. Granulocyte macrophage colony-stimulating factor as an adjuvant for hepatitis B vaccination: a meta-analysis. Vaccine 25: 709-718. 134. Stute, N., V. M. Santana, J. H. Rodman, M. J. Schell, J. N. Ihle, and W. E. Evans. 1992. Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. Blood 79: 2849-2854. 135. Zentner, G. M., R. Rathi, C. Shih, J. C. McRea, M. H. Seo, H. Oh, B. G. Rhee, J. Mestecky, Z. Moldoveanu, M. Morgan, and S. Weitman. 2001. Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. J. Control. Release 72: 203-215. 136. Cole, D. J., S. Gattoni-Celli, E. F. McClay, J. S. Metcalf, J. M. Brown, N. Nabavi, D. A. Newton, 3rd, C. B. Woolhiser, M. C. Wilson, and J. N. Vournakis. 1997. Characterization of a sustained-release delivery system for combined cytokine/peptide vaccination using a poly-N-acetyl glucosamine-based polymer matrix. Clin. Cancer. Res. 3: 867-873. 137. Nguyen, C. L., J. T. Bui, M. Demcheva, J. N. Vournakis, D. J. Cole, and W. E. Gillanders. 2001. Sustained release of granulocyte-macrophage colony-stimulating factor from a modular peptide-based cancer vaccine alters vaccine microenvironment and enhances the antigen-specific T-cell r | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/36974 | - |
dc.description.abstract | B型肝炎病毒感染為人類最重要的感染疾病之一,世界上約有三分之一以上的人曾被B型肝炎病毒所感染,有三億五千萬的人成為慢性肝炎帶原者,其中百分之十五到四十都有罹患B型肝炎相關疾病的風險,包括肝硬化及肝細胞癌。利用從病人血清分離或重組DNA技術所製造的B型肝炎表面抗原疫苗來進行免疫注射,是目前主要控制B型肝炎傳染以及散播的方式,但是百分之五到十的一般人卻無法藉由這些疫苗的免疫注射產生有效的B型肝炎表面抗原的抗體。這些人仍有被B型肝炎病毒感染的風險,因此需要發展更有效的疫苗來保護他們。而對於慢性B型肝炎感染的病人,目前的兼具抗病毒和免疫調節特性的藥物如干擾素及抑制B肝病毒的藥物如核苷、核苷酸衍生物都因為免疫的不反應或是抗藥的突變種,使得效果受到限制。依據目前的研究報告,一般皆認為,B型肝炎的細胞性免疫反應和肝臟相關疾病的進展是有關連的,但是真正的致病機轉並未清楚闡明。因此,本論文主要的研究目標如下:(1)開發更有效的B型肝炎疫苗來克服表面抗原不反應現象。(2)研究B型肝炎病毒引起免疫耐受性及造成肝細胞癌的致病機轉,希望藉此能對於慢性B型肝炎病毒感染的治療方法提供更明確的方向。
B型肝炎表面抗原的不反應現象和人類組織相容性抗原 (human leukocyte antigen) 及缺陷的輔助T細胞反應有關。某些組織相容性抗原,不易引發B型肝炎表面抗原的抗體反應。我們使用可以增強在啟動免疫反應時扮演重要角色的樹突細胞(Dendritic cells)呈現抗原能力的細胞激素(GM-CSF)當作疫苗的佐劑,來提供B型肝炎抗原呈現給輔助T細胞更好的環境,進而幫助B細胞來產生更強的抗體反應。我們應用新發展的PEG500-PLGA2880-PEG500高分子製備的熱感應凝膠(Hydrogel)製作新型的B型肝炎疫苗:在低溫(4℃)下凝膠呈液態時,混入B型肝炎表面抗原和細胞激素。當注射到動物,熱感應凝膠在溫度提高(37℃)後,會變成固態的膠狀,因此可以緩慢釋放B型肝炎抗原和細胞激素,達到讓抗原和細胞激素持續且同時刺激免疫反應的效果。我們的實驗結果顯示,在一般小鼠體內,可引起更強的抗體及T細胞增生反應。這樣的效果,必須是抗原與細胞激素同時局部的釋放才能達到。更重要的是,我們證明了在B型肝炎疫苗不反應小鼠(B10.M mice),僅需要注射一次新型疫苗,就可以克服不反應現象,引起顯著的抗體和T細胞免疫反應。而傳統的B型肝炎疫苗重覆注射在不反應小鼠也無法引發反應。進一步分析發現,經由熱感應凝膠所釋放的GM-CSF,吸引了在啟動免疫反應時扮演重要角色的樹突細胞,移動到疫苗注射部位附近的淋巴結,使淋巴結中樹突細胞的數量增多,共同刺激分子(costimulatory molecules, MHC II, CD40, CD80 and CD86)表現也更為成熟。根據以上結果,我們所製作的新型疫苗除了可以改善B型肝炎疫苗不反應現象,降低不反應現象的發生機會之外,也非常有潛力應用於其他種類疫苗的研發。 臨床以及實驗證據顯示,B型肝炎病毒特異性的免疫反應對於B型肝炎病毒所造成的肝臟損傷扮演很重要的角色,但是在研究B型肝炎致病機轉最主要的阻礙,在於缺乏對B型肝炎病毒可引發免疫反應的動物模式。我們實驗室最近發展出可以藉由腺相關病毒載體攜帶B型肝炎病毒基因,進入免疫健全小鼠的肝臟細胞。這些小鼠可持續製造B型肝炎病毒,血清學反應以及缺陷的特異性免疫反應與B型肝炎病毒慢性感染的病人類似。更重要的是,在大於十二個月後,所有的小鼠都產生肝臟腫瘤,並且大部分腫瘤都是肝細胞癌。因此,我們利用這個小鼠模式,來研究B型肝炎免疫耐受性的機轉,以及宿主免疫反應在B型肝炎病毒引起肝細胞癌所扮演的角色。我們的結果顯示,在施打AAV/HBV的小鼠,B型肝炎表面抗原在血液中的量和表面抗原特異性的CD8+ T細胞數目呈現負相關。當施打較低劑量的AAV/HBV後再進行DNA免疫,發現可以克服這些小鼠的免疫耐受性,在血清中偵測到表面抗原特異性的抗體反應。另一方面,我們沒有發現在施打AAV/HBV的小鼠的肝臟和脾臟中,調節性T細胞 (Tregs)有明顯增加的現象,調節性T細胞對於B型肝炎免疫耐受性的引發和維持會再進一步的探討。另一方面,我們發現計畫性死亡(PD-1)在施打AAV/HBV的小鼠的肝臟而非脾臟的CD8+ T細胞表現明顯增加。此結果表示PD-1和其接受器(PD-L1, B7-H1),與AAV/HBV造成的免疫耐受性有關連。因此,我們利用B7-H1基因剃除小鼠來進一步證實推論:結果發現,B型肝炎表面抗原的表現在施打AAV/HBV的B7-H1基因剃除小鼠明顯減少,而且B型肝炎表面抗原特異性的CD8+ T細胞也明顯增加。顯示在我們的AAV/HBV小鼠中,B7-H1對CD8+ T細胞的免疫耐受性的引發非常重要。最後,我們利用一系列的免疫缺陷小鼠,包括I-A (CD4+ T)、CD8a (CD8+ T)和CD1d (NKT) 基因剃除小鼠,來探討AAV/HBV造成的肝細胞癌的免疫致病機轉。我們發現 (1) 施打AAV/HBV的CD1d基因剔除小鼠的血清中麩胺酸丙酮酸轉胺酶 (ALT),在施打之後九個月有較明顯的上升,且在施打後九個月就陸續產生肝細胞癌,比野生型小鼠的肝細胞癌發生提早三個月發生。所有CD1d基因剔除的小鼠在施打AAV/HBV的十二到十五個月後都產生了肝細胞癌。(2) 和野生型小鼠比較,施打AAV/HBV的CD8 | zh_TW |
dc.description.abstract | Hepatitis B virus (HBV) infection remains one of the most important infectious diseases for human. More than a third of the world's population has been infected with HBV and more than 350 million are chronic carriers, of whom 15-40% is at risk of developing HBV-associated liver diseases, including cirrhosis and hepatocellular carcinoma (HCC). Vaccination with HBsAg derived from the plasma of HBV carriers or produced by recombinant DNA technology is the main strategy for effective control of the infection and viral transmission, but fails to induce adequate anti-HBs antibodies (Abs) in 5-10% healthy subjects, a phenomenon known as HBsAg non-responsiveness. These individuals remain at risk of HBV infection and thus there is a need for a more immunogenic vaccine for these non-responders. For those chronically infected HBV patients, therapeutic effects of current anti-HBV drugs, including interferon and nucleoside and nucleotide analogues, are hindered by unresponsiveness or emergence of drug-resistance mutants. It is generally believed that HBV-specific cellular responses are closely associated with disease progression in chronic HBV patients, but the exact pathogenic mechanisms remain unresolved. The major purposes of the present study are (1) to develop a potent HBV vaccine to overcome HBsAg non-responsiveness and (2) to investigate the possible immunopathogenic mechanisms associated with chronic HBV and HBV-associated HCC, which may have a major impact on the development of new treatment strategies.
The phenomenon of HBsAg non-responsiveness has been known to be closely related to human leukocyte antigen (HLA)-linked genes and impaired helper T (Th) cell responses to HBsAg in these subjects. We hypothesized that granulocyte-macrophage colony-stimulating factor (GM-CSF), a potent adjuvant in enhancing the antigen (Ag) presentation activity of APCs, might help generate Th cell responses in non-responders, subsequently providing help for B cells to produce anti-HBs Abs. A thermosensitive biodegradable co-polymer (hydrogel) system was used to co-deliver HBsAg and GM-CSF to achieve maximal local cytokine activity at the injection site. In responder mouse strains, hydrogel-formulated HBsAg plus GM-CSF vaccine (Gel/HBs+GM) elicited much higher anti-HBs Ab titers and Th cell proliferative responses than a commercial aluminum-formulated HBsAg vaccine or free HBsAg. The adjuvant effect of the Gel/HBs+GM vaccine was dependent upon the local release of GM-CSF. More importantly, the Gel/HBs+GM vaccine elicited high HBsAg-specific Ab titers and Th cell responses in B10.M mice, a mouse strain that does not respond to the current HBsAg vaccine because of its H-2 haplotype. Analysis of the draining lymph nodes of Gel/HBs+GM-treated mice revealed an elevated number of CD11c+ dendritic cells (DCs) showing enhanced expression of MHC class II and a variety of costimulatory molecules. These results demonstrate that hydrogel-formulated GM-CSF might represent a simple and effective method to generate next generation HBV vaccines for inducing anti-HBs Abs in non-responders. Clinical and experimental evidence suggests that antiviral immune responses play an important role for hepatocyte injury in chronic HBV infection. However, understanding the immunopathogenic mechanisms of chronic HBV is hindered by the lack of a convenient small animal model not being born tolerant to HBV and having convenient reagents for immune assays. Our lab has recently generated a chronic HBV disease model in immune competent mice by adeno-associated viral (AAV) vectors carrying the HBV genome. These AAV/HBV-transduced mice displayed similar serological profiles and impaired HBV-specific T cell responses to that observed in chronic HBV patients. Moreover, the majority of AAV/HBV-transduced mice developed HCC over one year after AAV/HBV transduction. Taking advantage of this HBV disease model, we proposed to investigate mechanisms involved in HBV-associated immune tolerance and the role of hepatic lymphocyte subpopulations in the AAV/HBV-associated HCC. Our results showed an inverse relationship between the circulating HBsAg level and the number of HBs-specific T cells in AAV/HBV-transduced mice. In mice transduced with lower doses of AAV/HBV, DNA immunization can effectively restore HBV-specific Ab and T cell responses. As for CD4+CD25+ regulatory T (Tregs), no significant increase of this suppressor T cell population was observed in AAV/HBV-transduced mice. In contrast, expression of programmed death-1 (PD-1) was significantly increased on hepatic but not splenic CD8+ T cells, suggesting that this inhibitory receptor was involved in induction of HBV immune dysfunction in AAV/HBV mice. This conclusion was further supported by experiments using programmed death 1 ligand 1 (PD-L1, B7-H1) knockout mice, in these mice AAV/HBV-transduction induced a much stronger HBV-specific CD8+ T cells response accompanied with decreased levels of serum HBsAg. Finally, a panel of gene knockout mice, I-A KO (deficient of CD4+ T cells), CD8 KO (deficient of CD8+ T cells), and CD1d KO (deficient of natural killer T was used to investigate the immunopathogenic mechanisms of HCC developed in AAV/HBV-transduced mice. CD1d KO mice showed increased serum alanine aminotransferase (ALT) from 9 months after AAV/HBV transduction, and developed liver tumors at the age of 9 month-old; at least three months earlier than similarly treated wild-type mice. All AAV/HBV-transduced CD1d KO mice developed macroscopically visible liver tumor nodules between 12 and 15 months after AAV/HBV transduction. AAV/HBV-transduced CD8 KO mice had lower tumor incidence and smaller tumor size compared with similarly treated wild-type mice, suggesting that CD8+ T cells play a critical but not essential role in AAV/HBV-associated HCC. The detailed mechanisms of tumor formation associated with these immune cells need to be further investigated in the future. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T15:17:25Z (GMT). No. of bitstreams: 1 ntu-100-D93445008-1.pdf: 13315756 bytes, checksum: b389121ab6e6bd687c793ccdd64ef2d1 (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | Table of contents I
中文摘要 1 Abstract 4 Introduction 8 1 Hepatitis B virus 8 2 Outcome of HBV infection (Immunity to HBV) 9 2.1 HBV acute infection 10 2.2 The CD8+ T cell response 11 2.3 The CD4+ T cell response 12 2.4 Chronic HBV infection 13 3 HBV vaccine 13 4 Immunosuppressive Mechanisms During Viral Infectious Diseases 14 4.1 Effect of HBV dose on HBV mediated tolerance 15 4.2 Effect of Tregs on HBV mediated tolerance 15 4.3 Effect of PD-1/ PD-L1 pathway on HBV mediated tolerance 17 5 HBV-associated liver diseases 18 5.1 Integration of hepatitis B virus DNA 19 5.2 Role of viral proteins 19 5.3 Immune-mediated liver injury 20 6 HBV therapy and therapeutic vaccines 21 7 Goal of studies 23 Materials and Methods 24 1 Animals 24 2 Immunization 24 3 Ab assays 26 4 Lymphocyte proliferation assay 26 5 DC migration assays 27 6 Preparation of AAV vectors 28 7 AAV injections and regulatory T cell depletion 28 8 Isolation of intrahepatic leukocytes 29 9 Serological analysis 29 10 IFN-γ ELISPOT assay 29 11 Flow cytometric analysis of splenocytes and intrahepatic leukocytes 30 12 Statistics 31 Results 32 1 The Gel/HBs+GM vaccine enhances HBsAg-specific humoral and cellular immune responses 32 2 The Gel/HBs+GM vaccine overcomes immune non-responsiveness to HBsAg 34 3 Hydrogel-delivered GM-CSF increases the number and activation status of DCs. ………………………………………………………………………………….35 4 Effect of HBV does on HBV-induced immune tolerance 37 5 Effect of regulatory T cells on HBV-induced immune tolerance 39 6 Effect of PD-1/ PD-L1 pathway on HBV-induced immune tolerance 42 7 Pathogenic role of lymphocyte subpopulations in HBV-associated HCC 45 Discussion 49 1 Non-responsiveness to HBV vaccine 49 2 Strategies to overcome nonresponsiveness to HBsAg 50 3 Adjuvant effect of GM-CSF 51 4 HBV immunity and HBV-associated liver diseases 56 5 AAV/HBV dosage in AAV/HBV-induced immune tolerance 57 6 Treg in AAV/HBV-induced immune tolerance 59 7 PD-1/PD-L1 pathway in AAV/HBV-induced immune tolerance 60 8 Other inhibitory marker in chronic infection 61 9 HBV therapy and therapeutic vaccines to break tolerance 62 10 HCC mechanism: Immune-mediated liver injury 64 References 67 圖目錄 Figure 1. Hydrogel-delivered HBsAg and GM-CSF vaccine enhanced production of anti-HBs Abs in mice. 81 Figure 2. Hydrogel-delivered HBsAg and GM-CSF vaccine enhanced production of anti-HBs antibodies in different strain of mice. 82 Figure 3. Hydrogel-delivered HBsAg and GM-CSF vaccine enhanced both IgG1 and IgG2a Abs. 83 Figure 4. Gel/HBs+GM vaccine enhances the production of anti-HBs Abs in B10.M mice. 84 Figure 5. Gel/HBs+GM vaccine overcomes immune non-responsiveness to HBsAg. 85 Figure 6. Gel/GM-CSF increased migration of transferred and endogeneous DCs to draining LNs. 86 Figure 7. Gel/GM increased frequencies of DCs in the draining LNs in B10.M mice. 87 Figure 8. Gel/HBs+GM increased frequencies and maturation state of DCs in the draining LNs in B10.M mice. 88 Figure 9. Mechanism of Gel/HBs+GM vaccine. 89 Figure 10. Effect of HBV doses on HBsAg level in AAV/HBV-transduced mice. 90 Figure 11. Effect of HBV doses on HBsAg-specific CD8+ T cell responses in AAV/HBV-transduced mice. 91 Figure 12. Effect of HBV doses on HBsAg and anti-HBs Abs in AAV/HBV-transduced mice. 92 Figure 13. Hepatic and splenic Tregs induced by AAV/HBV transduction. 93 Figure 14. Effect of CPA treatment on Tregs population in AAV/HBV-transduced mice. 94 Figure 15. CPA treatment resulted in reduction of HBsAg and HBeAg expression in AAV/HBV-transduced mice. 95 Figure 16. CPA treatment induced activation of non-specific CD8+ T cells. 96 Figure 17. Characterization of Tregs cells in Foxp3-GFP TG mice. 97 Figure 18. Analysis of hepatic Tregs cells in AAV/HBV-transduced Foxp3-GFP TG mice. 98 Figure 19. AAV/HBV transduction induced upregulated PD-1 expression on liver CD8+ T cells. 99 Figure 20. Reduction of HBsAg expression in AAV/HBV-transduced B7-H1 KO mice. 100 Figure 21. Effect of PD-1/PD-L1 signaling pathway on intrahepatic leukocytes populations in AAV/HBV-transduced mice. 101 Figure 22. Blocking PD-1/PD-L1 pathway increased CD69 expression in AAV/HBV-transduced mice. 102 Figure 23. Blocking PD-1/PD-L1 pathway increased PD-1 expression in AAV/HBV-transduced mice. 103 Figure 24. Blocking PD-1/PD-L1 pathway increased HBs-specific T cell responses in AAV/HBV-transduced mice. 103 Figure 25. AAV/HBV transduction induces persistent HBV expression in different immune KO mice. 104 Figure 26. Kinetics of ALT in different AAV/HBV-transduced immune-deficient mice. 105 Figure 27. Effect of various lymphocyte populations in AAV/HBV-mediated tumor formation. 106 Figure 28. Histological analysis of liver tumor from AAV/HBV-transduced or PBS injected immune deficient mice. 107 表格目錄 Table I. Gel/HBs+GM vaccine enhances HBs-specific T cell proliferative responses. 108 Table II. Incidences of liver tumors in AAV/HBV transduced or PBS injected mice at 12 month post-treatment. 109 | |
dc.language.iso | en | |
dc.title | 發展新型B型肝炎疫苗來克服不反應現象及研究慢性B型肝炎病毒與肝細胞癌的免疫致病機轉 | zh_TW |
dc.title | Development of novel HBV vaccines to overcome nonresponsiveness and studies of immunopathogenic mechanisms of chronic HBV and HBV-associated hepatocellular carcinoma | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 吳慧琳,賈景山,張明富,紀威光 | |
dc.subject.keyword | B型肝炎病毒,不反應現象,細胞激素,熱感應凝膠,免疫耐受性,肝細胞癌,免疫致病機轉, | zh_TW |
dc.subject.keyword | Hepatitis B virus,non-responsiveness,hydrogel,granulocyte-macrophage colony-stimulating factor,immune tolerance,immunopathogenesis,hepatocellular carcinoma, | en |
dc.relation.page | 110 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2011-08-11 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 微生物學研究所 | zh_TW |
顯示於系所單位: | 微生物學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 13 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。